Korro Bio (Korro Bio) Momentum Rank : 0 (As of May. 20, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Korro Bio Momentum Rank?

Korro Bio has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Korro Bio Momentum Rank Related Terms

Thank you for viewing the detailed overview of Korro Bio's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Korro Bio (Korro Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Korro Bio Inc (NAS:KRRO) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Kendall Square, Suite 6-401, Building 600-700, Cambridge, MA, USA, 02139

Website

https://www.korrobio.com

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Executives

David L. Lucchino	director, officer: President and CEO	C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Rick Yang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Edward T Mathers	10 percent owner	C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Nessan Bermingham	director	890 WINTER STREET, WALTHAM MA 02451
Atlas Venture Associates Xi, Llc	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
New Enterprise Associates 17, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 17, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea 17 Gp, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund Ii, L.p.	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Llc	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Lp	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Steve Colletti	officer: Chief Scientific Officer	C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139
Shelby J. Walker	officer: See Remarks	C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139

Korro Bio (Korro Bio) Headlines

From GuruFocus

Korro Announces $70 Million Private Placement

By Marketwired • 04-18-2024